Mucocutaneous leishmaniasis masquerading as wegener granulomatosis

Journal of Clinical Rheumatology

Volumn 16, Issue 3, 2010, Pages 125-128

  Brahn, Ernest ^a   Pegues, David A ^a   Yao, Qingping ^a   Craft, Noah ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Amphotericin B; Meglumine antimoniate; Mucocutaneous leishmaniasis; Pentavalent antimony; Wegener's granulomatosis

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; MEGLUMINE ANTIMONATE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ADULT; ALOPECIA; AMERICAN LEISHMANIASIS; ARTICLE; CASE REPORT; CHRONIC INFLAMMATION; DIAGNOSTIC ERROR; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GRANULOMATOUS INFLAMMATION; HUMAN; HUMAN TISSUE; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; NASAL BIOPSY; NOSE DISEASE; NOSE SEPTUM PERFORATION; NOSE ULCER; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; REMISSION; SECONDARY AMENORRHEA; SINUSITIS; SKIN BIOPSY; SOFT PALATE; WEGENER GRANULOMATOSIS;

ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; BRAZIL; CALIFORNIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEISHMANIASIS, MUCOCUTANEOUS; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; REFERRAL AND CONSULTATION; WEGENER GRANULOMATOSIS;

EID: 77951069747     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181d52c96     Document Type: Article

References (16)

1. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33:1101-1107.
2. Schriefer A, Wilson ME, Carvalho EM. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis. 2008;21:483-488.
3. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007;45:21-25.
4. Drugs for parasitic infections. Med Lett. 2007;5(suppl):1-15.
5. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004;117:39-50.
6. Stone JH. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 2003;48:2299-2309.
7. Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis: a literature review and meta-analysis. Ann Intern Med. 1995;123: 925-932.
8. Scatena P, Messina F, Gori S, et al. Visceral leishmaniasis in a patient treated for polyarteritis nodosa. Clin Exp Rheumatol. 2003;21(6 suppl 32):S121-S123.
9. Lindoso JA, Barbosa RN, Posada-Vergara MP, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol. 2009;160:311-318.
10. Correa EB, Cunha JM, Bunn-Moreno MM, et al. Cyclophosphamide affects the dynamics of granuloma formation in experimental visceral leishmaniasis. Parasitol Res. 1992;78:154-160.
11. Otero AC, Piuvezam MR, Cunha JM, et al. Cyclophosphamide blocks both antigen-specific and polyclonal immunoglobulin responses in experimental visceral leishmaniasis. Int J Immunopharmacol. 1993;15:255-259.
12. Faria DR, Gollob KJ, Barbosa J Jr, et al. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun. 2005; 73:7853-7859.
13. Eidsmo L, Nylen S, Khamesipour A, et al. The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis. Am J Pathol. 2005;166:1099-1108.
14. Liese J, Schleicher U, Bogdan C. The innate immune response against Leishmania parasites. Immunobiology. 2008;213:377-387.
15. Rocha FJ, Schleicher U, Mattner J, et al. Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice. Infect Immun. 2007;75:3823-3832.
16. Grimaldi G Jr, Tesh RB, Mahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg. 1989;41:687-725.